Glycoprotein News and Research

RSS

Tulane University receives $12 million NIH grant to develop drug and vaccine against Lassa fever

The National Institutes of Health has awarded Tulane University more than $12 million to test a promising drug treatment against Lassa fever and develop a vaccine against the deadly disease endemic in parts of West Africa.

11 Jul 2017

Researchers identify key Lassa virus structure using powerful Argonne X-rays

Before Ebola virus ever struck West Africa, locals were already on the lookout for a deadly pathogen: Lassa virus.

13 Jun 2017

Researchers discover connection between processes that keep the heart from repairing itself

Heart muscle is one of the least renewable tissues in the body, which is one of the reasons that heart disease is the leading cause of death for both men and women in the United States, according to the Centers for Disease Control and Prevention.

5 Jun 2017

TSRI study reveals first-ever structure of Lassa virus protein

Before Ebola virus ever struck West Africa, locals were already on the lookout for a deadly pathogen: Lassa virus. With thousands dying from Lassa every year - and the potential for the virus to cause even larger outbreaks- researchers are committed to designing a vaccine to stop it.

1 Jun 2017

Scripps scientists make important advance in HIV vaccine design

Scientists at The Scripps Research Institute (TSRI) have made another important advance in HIV vaccine design. The development was possible thanks to previous studies at TSRI showing the structures of a protein on HIV’s surface, called the envelope glycoprotein. The scientists used these structures to design a mimic of the viral protein from a different HIV subtype, subtype C, which is responsible for the majority of infections worldwide.

29 May 2017

New findings could lead to first broadly effective ebolavirus therapies and vaccines

After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals against all three major disease-causing ebolaviruses.

19 May 2017

Researchers explore new treatment combination for pediatric patients with Hodgkin lymphoma

Pediatric and young adult patients whose Hodgkin lymphoma has recurred or is resistant to initial treatment can achieve remission and even cure with secondary treatments.

18 May 2017

Antidepressant improves drug delivery across the blood-brain barrier, rat study shows

NIH rat study suggests amitriptyline temporarily inhibits the blood-brain barrier, allowing drugs to enter the brain.

27 Apr 2017

Early blood test can predict vaccine immunogenicity

Within seven days of vaccination, a blood test early after vaccination can predict whether vaccines based on living, modified viruses have had the desired effect.

26 Apr 2017

Microbiologists accurately predict evolution of HIV surface proteins using financial math models

What do particle diffusion in liquids and stock price prediction have to do with building a better HIV vaccine? According to University of Iowa microbiologist Hillel Haim, you can apply concepts from the first two to predict the evolution of HIV surface proteins, information that can then be used to design better vaccines.

7 Apr 2017

TSRI scientists develop novel method to analyze glycan shield on HIV’s glycoprotein

HIV is a master of disguise. The virus uses a shield of sugar molecules, called glycans, to hide from the immune system and block antibodies from attacking it.

28 Mar 2017

New study examines immune responses to Ebola vaccines at one year after immunization

Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.

14 Mar 2017

Investigational RSV vaccine protects cattle from respiratory diseases

A novel vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, protected cattle from respiratory syncytial virus (RSV) infection, according to research published online in npj Vaccines on March 8.

10 Mar 2017

Glycoprotein News and Research

Tulane University receives $12 million NIH grant to develop drug and vaccine against Lassa fever

Researchers identify key Lassa virus structure using powerful Argonne X-rays

Researchers discover connection between processes that keep the heart from repairing itself

TSRI study reveals first-ever structure of Lassa virus protein

Scripps scientists make important advance in HIV vaccine design

New findings could lead to first broadly effective ebolavirus therapies and vaccines

Researchers explore new treatment combination for pediatric patients with Hodgkin lymphoma

Antidepressant improves drug delivery across the blood-brain barrier, rat study shows

Early blood test can predict vaccine immunogenicity

Microbiologists accurately predict evolution of HIV surface proteins using financial math models

TSRI scientists develop novel method to analyze glycan shield on HIV’s glycoprotein

New study examines immune responses to Ebola vaccines at one year after immunization

Investigational RSV vaccine protects cattle from respiratory diseases

Emory researchers uncover novel link between SV2C protein and Parkinson's disease

New genital herpes vaccine candidate shows promising results in preclinical tests

Type 2 diabetes drug may someday help combat breast and ovarian cancers

Inflammatory marker detected in blood tests can better predict risk of death, study suggests

Purdue University biochemist develops novel method for identifying cancer biomarkers

Ebola mutation increased infectivity

Novel approach could help counter Influenza A virus in immune-compromised patients

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News